• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, July 2, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home Headlines

Follow-up cholesterol testing reduces risk of reocurrence for heart attack and stroke…

Bioengineer.org by Bioengineer.org
January 21, 2018
in Headlines, Health, Science News
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Intermountain Medical Center.

If you have a heart attack or stroke, it's important to get your "bad" cholesterol measured by your doctor on a follow up visit. Researchers have found that one step is significantly associated with a reduced risk of suffering another serious cardiovascular episode.

The new research, conducted by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City, found that patients who don't follow up with their doctor by getting a low-density lipoprotein (LDL) cholesterol test following a heart attack or stroke are significantly more likely to have a reccurrence.

Researchers found a significant and clinically meaningful difference in major adverse outcomes — including death, a heart attack, a stroke, and a vascular bypass or an angioplasty — based on whether or not a patient has a follow-up measurement of their LDL cholesterol.

Researchers say the results of the study suggest LDL cholesterol levels should be regularly measured after an initial heart attack or stroke. LDL is the "bad" cholesterol, and main source that becomes part of the plaque that clogs arteries and makes heart attacks and strokes more likely.

"It's clear that anyone with a previous heart problem caused by clogged arteries should be taking a cholesterol-lowering medication," said Kirk U. Knowlton, MD, lead author of the study and director of cardiovascular research at the Intermountain Medical Center Heart Institute.

The study of more than 60,000 patients with known heart disease, cerebrovascular disease or peripheral artery disease, including stroke and heart attack patients, showed the major adverse clinical event rate was lower in both patients who took cholesterol-lowering statins and those who didn't if their LDL was measured.

"The large difference is surprising. The risk of dying after three years with no LDL follow-up is 21 percent versus 5.9 percent for patients who have an LDL follow-up," said Dr. Knowlton.

Results of the Intermountain Medical Center Heart Institute study will be presented at the 2017 Scientific Sessions of the American Heart Association, in Anaheim, CA, at 3:15 pm, PT, on Nov. 12.

The Intermountain Medical Center Heart Institute study reviewed Intermountain Healthcare's enterprise data warehouse, one of the nation's largest depositories of clinical data, to identify all adults who came to one of Intermountain's 22 hospitals for the first time with a heart attack or stroke. These included patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease admitted between January 1, 1999, and December 31, 2013.

Researchers looked at patients who survived and were followed for three years or more, or until their death. Patient demographics, history, prescribed medications, and whether LDL was measured was analyzed. "We looked at a variety of parameters — which represents one real benefit Intermountain offers to medical researchers and providers nationwide," Dr. Knowlton said. "They've been collecting data since the 1990s and it's a phenomenal data set."

The study compared 62,070 patients in the database who met the study criteria. The average age was 66 years old, with 65 percent of patients being male. Of those who met the criteria, 69.3 percent had coronary artery disease, 18.6 percent had cerebrovascular disease, and 12.1 percent had peripheral arterial disease when they came to the hospital with their first heart attack or stroke.

Researchers found the risk of a patient having a secondary event or dying decreased in those who had a follow-up LDL test before a subsequent adverse outcome or before the end of their follow-up.

Dr. Knowlton says the study reinforces how important it is for patients to continually take their cholesterol medications.

"Patients need to know that if they've had a cardiovascular event, continuing to take their medications will not only lower their LDL, but substantially lower their risk of having another event," he noted. "We need to emphasize to doctors how important it is to follow up therapy for patients with measurement of their LDL cholesterol. And patients need to talk to or ask their doctors about the test, especially if they've had a heart attack or stroke."

###

Other members of the Intermountain Medical Center Heart Institute team include: Heidi T. May, PhD, MSPH; Tami L. Blair, BS; Jeffrey L. Anderson, MD; Donald L. Lappe, MD; Joseph B. Muhlestein, MD.

The Intermountain Medical Center Heart Institute, part of the Intermountain Healthcare system based in Salt Lake City, is one of the premier cardiovascular centers in the country.

Media Contact

Jess C. Gomez
[email protected]
801-718-8495
@IntermtnMedCtr

http://www.ihc.com

Share12Tweet8Share2ShareShareShare2

Related Posts

Steatosis Drives Liver Metastasis Diversity in CRC — Medicine

Steatosis Drives Liver Metastasis Diversity in CRC

July 2, 2026

Unlocking the Mysteries of Alzheimer’s Disease

July 2, 2026

Pensoft Introduces New Peer-Reviewed Journal of Regeneration to Advance Restorative Biology Across Species

July 2, 2026

Evolution-Inspired Biosensors Revolutionize Lipid Tracking in Real Time

July 2, 2026
Please login to join discussion

POPULAR NEWS

  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15
  • KTU Researchers Explore Ultrasound’s Role in Enhancing Blood Flow Beyond Diagnostics

    53 shares
    Share 21 Tweet 13

About

BIOENGINEER.ORG

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Steatosis Drives Liver Metastasis Diversity in CRC

Unlocking the Mysteries of Alzheimer’s Disease

Pensoft Introduces New Peer-Reviewed Journal of Regeneration to Advance Restorative Biology Across Species

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 83 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.